Get started
Author

Irl Brian Greenwell

Observed names: Greenwell, Irl Brian, I Brian Greenwell, I. B. Greenwell, I. Brian Greenwell, I. Greenwell, I.B. Greenwell
ORCID: 0000-0003-2752-8078
Observed ORCID: 0000-0003-2752-8078
OpenAlex ID: A5012121701
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
2017 · I Brian Greenwell, Andrew Ip, et al. · PubMed · 119
Disaster 101: A Novel Approach to Disaster Medicine Training for Health Professionals
2010 · Lancer A. Scott, Deborah S. Carson, et al. · Journal of Emergency Medicine · 64
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy
2018 · I. Brian Greenwell, Ashley D. Staton, et al. · Cancer · 58
PDF
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow
2017 · I. B. Greenwell, C. R. Flowers, et al. · Expert Review of Anticancer Therapy · 54
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
2023 · Yazeed Sawalha, Subir Goyal, et al. · Blood Advances · 29
PDF
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
2023 · Narendranath Epperla, Rina Li Welkie, et al. · Journal of Hematology & Oncology · 21
PDF
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study
2023 · Narendranath Epperla, Qiuhong Zhao, et al. · Blood Advances · 16
PDF
Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN)
2022 · James A. Davis, David A. Rizzieri, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13
Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel
2021 · Jason T. Romancik, Subir Goyal, et al. · Blood · 12
IKAROS gain of function disease: Allogeneic hematopoietic cell transplantation experience and expanded clinical phenotypes
2024 · Natchanun Klangkalya, Jennifer Stoddard, et al. · Clinical Immunology · 10
Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy
2023 · Yucai Wang, Melissa C. Larson, et al. · Blood · 10
Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis
2020 · Yazeed Sawalha, Subir Goyal, et al. · Blood · 10
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
2022 · Narendranath Epperla, Qiuhong Zhao, et al. · Journal of Hematology & Oncology · 9
PDF
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
2025 · Yucai Wang, Melissa C. Larson, et al. · Blood Advances · 7
PDF
Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
2021 · Irl Brian Greenwell, James Davis, et al. · Journal of Clinical Oncology · 7
Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation
2021 · Brian Hess, James Kalmuk, et al. · Cancer Genetics · 5
Postibrutinib relapse outcomes for patients with marginal zone lymphoma
2022 · Narendranath Epperla, Qiuhong Zhao, et al. · Blood Advances · 4
When to use stem cell transplant in mantle cell lymphoma
2019 · I. Brian Greenwell, Jonathon B. Cohen · Expert Review of Hematology · 4
PDF
Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics
2016 · Ashley D. Staton, Irl Brian Greenwell, et al. · Blood · 4
Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data
2023 · Swami P. Iyer, Sabarish R. Ayyappan, et al. · Blood · 3
Transplant and chimeric antigen receptor T-cell therapies in elderly patients with lymphoma, a narrative review
2022 · I. Brian Greenwell, Parastoo B. Dahi · Annals of Lymphoma · 3
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
2024 · Yucai Wang, Melissa C. Larson, et al. · Journal of Clinical Oncology · 2
Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy
2023 · Jonathan Bakos, Silvia Escribano Serrat, et al. · Blood · 2
Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
2022 · Pamela B. Allen, Subir Goyal, et al. · Blood · 2
Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
2022 · Narendranath Epperla, Rui Li, et al. · Blood · 2
Works count: 55
Citation count: 484
H-index: 10
I10-index: 12
Year
Topic
Type